Cure8 research brief
MAIT cells are part of the gut immune environment and this study suggests their regulatory and inflammatory programs are altered in active Crohn’s disease.
Treatments such as corticosteroids and upadacitinib can change MAIT cell responses in laboratory tests, which may be relevant to understanding immune effects of therapies.
Researchers studying IBD immunology, clinicians interested in immune effects of IBD treatments, and patients curious about emerging immunology research in Crohn’s disease.
This study examined mucosa-associated invariant T (MAIT) cells in Crohn’s disease using blood and intestinal samples and transcriptional analysis.
The authors report fewer circulating MAIT cells with reduced IFN-γ, TNF and cytotoxic responses in patients, and that IL-10+ (regulatory) and IL-17A+ MAIT cell programs were specifically impaired during active disease but more preserved in remission.
MAIT cells in intestinal tissue showed different transcriptional signatures by location: intra-epithelial MAIT cells had a tissue-resident regulatory profile while lamina propria MAIT cells had activation/recruitment markers.
The authors tested drug effects in vitro and found corticosteroids and the JAK inhibitor upadacitinib reduced overall MAIT activation; however, upadacitinib also increased GM-CSF and IL-17A under combined antigen+IL-18 stimulation in these experiments.
These findings suggest MAIT cell functional patterns vary with disease activity, tissue localization, and exposure to certain therapies. The work is presented as an experimental immunology study (transcriptional profiling and in vitro assays) and does not report clinical outcomes or treatment recommendations.
This is a laboratory-based immunology study (transcriptional profiling and in vitro stimulation assays) reported in a peer-reviewed journal abstract; it does not provide clinical trial results or change clinical care. Drug effects reported are from in vitro experiments and may not reflect effects in patients.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: US National Institutes of Health - RO1 AI14807-01A1; Australian National Health and Medical Research Council - 2009551; Swedish Research Council - 2023-02857; Petrus and Augusta Hedlunds Foundation - M-2025-2694; Ruth and Richard Julin Foundation - 2025-00366; the Center for Innovative Medicine - 989096; Swedish Cancer Society - 23-2912Pj; Australian Research Council - CE200100012; Swedish Heart-Lung Foundation - 20230551
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
